University System of Maryland

John M Hamlyn

Mordecai P Blaustein

James H Ludens

William Rodney Mathews

Jed F Fisher

Douglas W Harris

Donald W DuCharme

Frederic Mandel

Ling Chen

A Avinoam Kowarski

Stephen Gottlieb

The present invention provides a method of preventing, reducing or attenuating acute kidney injury in a subject at risk of experiencing a transient increase in kidney ischemia or hypoxia, comprising administering to the subject an effective amount of an agent that binds to and neutralizes endogenous ouabain (EO).

Methods for preventing acute kidney injury

Methods for diagnosing pre-hypertension, hypertension, congestive cardiomyopathy, renal failure, salt-sensitivity and adenomas and endocrine cell hyperplasias are disclosed. Also disclosed are methods for monitoring hypertension therapy, congestive cardiomyopathy therapy, renal failure therapy and adenoma and endocrine cell hyperplasia therapy. These methods involve using an antibody having binding specificity to ouabain to immunologically measure the level of human ouabain in body fluid or tissue of a subject. Additionally, methods for treating a hypertensive subject by inducing passive or active immunity to human ouabain in the subject are disclosed, along with an antibody having binding specificity for ouabain.

Antibody having binding specificity for human ouabain

Methods for treating hypertension

Methods using an antibody having binding specificity to ouabain to immunologically measure the level of human ouabain in body fluid or tissue of a subject are disclosed.

Immunoassay for detecting human ouabain

Methods for diagnosing pre-hypertension, hypertension, congestive cardiomyopathy, renal failure, salt-sensitivity and adenomas and endocrine cell hyperplasias are disclosed. Also disclosed are methods for monitoring hypertension therapy, congestive cardiomyopathy therapy, renal failure therapy and adenoma and endocrine call hyperplasia therapy. These methods involve using an antibody having binding specificity to ouabain to immunologically measure the level of human ouabain in body fluid or tissue of a subject. Additionally, methods for treating a hypertensive subject by inducing passive or active immunity to human ouabain in the subject are disclosed, along with an antibody having binding specificity for ouabain.

Assay methods involving ouabain

A method for measuring plasma levels of an inhibitor of (Na.sup.+ +K.sup.+)ATPase associated with hypertension comprising:

Growing community of inventors

Baltimore, MD, United States of America

John M Hamlyn